Take a moment to care for the ones you love—and yourself! Prioritizing health and screening can make all the difference. Check out the American Cancer Society screening guidelines by age: https://bit.ly/3OUB3WM
Exosome Diagnostics, a Bio-Techne brand
生物技术研究
Waltham，MA 8,097 位关注者
ExoDx Prostate is the only exosome-based, non-DRE, simple urine test to assess risk for HGPCa and guide biopsy decision.
关于我们
Exosome Diagnostics, Inc. is commercializing minimally invasive molecular diagnostics in blood and urine to enable doctors to select optimal therapies for cancer and other diseases. Exosomes are lipid bilayer covered microvesicles shed by solid tumors into body fluids, such as blood and urine. Exosomes contain nucleic acid profiles of cancers and other diseases. In published studies, Exosome Diagnostics has demonstrated the ability to extract exosomes from the blood and urine of patients, and to detect with high sensitivity and specificity key genes and gene mutations associated with a variety of cancers.
- 网站
-
https://www.exosomedx.com
Exosome Diagnostics, a Bio-Techne brand的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Waltham，MA
- 类型
- 私人持股
- 创立
- 2008
- 领域
- exosomes and microvesicles、biomarkers、diagnostic development和biofluids
地点
Exosome Diagnostics, a Bio-Techne brand员工
动态
-
Missed out on #GU25? Catch up on the highlights from these sources: UroToday + GU OncToday: https://bit.ly/41daJvL Video Journal of Oncology (VJOncology): https://bit.ly/41daJMh OncLive: https://bit.ly/41daKjj CURE TODAY: https://bit.ly/4gYszs4
-
Incidences of advanced #prostatecancer in California have risen markedly over the past decade- see how in a new study by University of California, San Francisco. https://bit.ly/4biqypo #pcsm
-
The American Cancer Society’s 2025 Cancer Statistics have been released- watch Matthew Cooperberg, MD, from UCSF Department of Urology review the data with Urology Times: https://bit.ly/3CY4yUh #pcsm
-
Every patient deserves access to better cancer care. At ExoDx, we’re harnessing the power of exosomal RNA to enable more accurate, personalized #cancer diagnostics. Together, we can #CloseTheCareGap. #WorldCancerDay
On #WorldCancerDay and every day, our team is working to deliver the innovation that researchers and clinicians rely on to catalyze advances in cancer research. Driven by our passion for science, we are constantly pushing for better answers – and better outcomes for cancer patients.
-
Join us at the 25th Annual Scientific Meeting in Urologic Oncology, December 4 – 6, 2024 in Dallas, TX. Participate in discussions led by internationally renowned urologic oncologists, and learn more about the utility of biomarkers with Dr. Pavlovich presenting a multi-center prospective trial evaluating the ExoDx Prostate Test and men with Grade Group 1 cancer.
-
Could boosting a precursor of vitamin K slow progression of early stage #prostatecancer? Promising results in mice have given by CSHL School of Biological Sciences researchers hope. https://lnkd.in/gMmQhZHt #pcsm
-
Heart disease is a major cause of death in men with #prostatecancer - could cancer treatments be contributing to the problem? A new Nature article explores the issue: https://lnkd.in/gt2P49V8 ?? Watch this Urology Times video for more: https://bit.ly/40ZXGiN
-
Tomorrow kicks off the annual DrTalks Prostate Cancer Summit, featuring leading experts around the country sharing insights and advice on prostate health. Join Dr. Geo Espinosa and Dr. Punnen on Day 2 to discover more about prostate cancer screening methods. Register before it starts: https://lnkd.in/grP6qYqT
-
Why some prostate cancers shouldn’t be called ‘cancer’ - University of California, San Francisco expert Matthew Cooperberg argues that patients with low-grade prostate cancer should not be burdened with a cancer diagnosis that has zero capacity to harm them. https://lnkd.in/gX9jxCnr